Porokeratosis - I-Porokeratosis
☆ Kwiziphumo zika-2022 ze-Stiftung Warentest ezivela eJamani, ukwaneliseka kwabathengi ngeModelDerm bekungaphantsi kancinci kunokubonisana nge-telemedicine ehlawulweyo.
Iincam eziqinileyo ziluphawu.
References
Porokeratosis yimeko yolusu enqabileyo ephawulwa ziingxaki zekeratinization, ezikhokelela ekuphakameni, amabala amile okwesangqa okanye amaqhuma arhabaxa eluswini. Isici sayo esicacileyo phantsi kwe-microscope kubukho be-cornoid lamella, ilungiselelo elithile leeseli kuluhlu oluphezulu lwesikhumba. Porokeratosis iza ngeendlela ezahlukeneyo (disseminated superficial actinic porokeratosis, classical porokeratosis of Mibelli, porokeratosis palmaris plantaris et disseminatum, linear porokeratosis) . Kubalulekile ukuqaphela ukuba porokeratosis inokuthi ikhule ibe ngumhlaza wolusu. Eyona ndlela ingcono yokuxilonga porokeratosis kukusebenzisa i-biopsy yomda onyusiweyo, nangona okwangoku kungekho ndlela yonyango eqhelekileyo.
Porokeratosis is an uncommon dermatologic disorder. It is a disorder of keratinization that presents with keratotic papules or annular plaques with an elevated border. It has a distinct histologic hallmark of cornoid lamella, which is a column of tightly fitted parakeratotic cells in the upper epidermis. There are multiple clinical variants of porokeratosis, including disseminated superficial actinic porokeratosis, classical porokeratosis of Mibelli, porokeratosis palmaris plantaris et disseminatum, and linear porokeratosis. Porokeratosis is a precancerous lesion that can undergo malignant transformation. Evaluation of porokeratosis is best with a biopsy of the elevated border. There are no standard guidelines for treatment.
Porokeratosis is an uncommon dermatologic disorder. It is a disorder of keratinization that presents with keratotic papules or annular plaques with an elevated border. It has a distinct histologic hallmark of cornoid lamella, which is a column of tightly fitted parakeratotic cells in the upper epidermis. There are multiple clinical variants of porokeratosis, including disseminated superficial actinic porokeratosis, classical porokeratosis of Mibelli, porokeratosis palmaris plantaris et disseminatum, and linear porokeratosis. Porokeratosis is a precancerous lesion that can undergo malignant transformation. Evaluation of porokeratosis is best with a biopsy of the elevated border. There are no standard guidelines for treatment.
Disseminated superficial actinic porokeratosis (DSAP) sisifo sokuphazamiseka kwekeratinization. Yenye kwiintlobo ezintandathu ze porokeratosis, kwaye ichaphazela iindawo ezinkulu xa kuthelekiswa nezinye (linear, Mibelli's, punctate, palmoplantar disseminated, superficial porokeratosis) . Uhlobo olugqabhukileyo lwe-porokeratosis luhlala lunxibelelana nomhlaza, ubuthathaka bokungakhuseleki, okanye ukudumba. Izinto eziyingozi zibandakanya imizila yemfuza, ukucinezelwa kwamajoni omzimba kunye nokuba sesichengeni selanga. I-DSAP iqala njengamaqhuqhuva apinki okanye amdaka ngebala anemiphetho ephakanyisiweyo kwindawo ebekwe lilanga, ngamanye amaxesha ibangele ukurhawuzelelwa kancinci. Unyango luyahluka kwaye lunokubandakanya iikhrimu ezisematheni, unyango olulula, okanye amayeza afana ne-5-fluorouracil okanye i-retinoids. Ezi zilonda zithathwa ngokuba precancerous, kunye 7. 5 - 10 % ithuba lokujika ibe squamous cell okanye basal cell carcinoma.
Disseminated superficial actinic porokeratosis (DSAP) is a disease of disordered keratinization. Disseminated superficial actinic porokeratosis is one of six variants of porokeratosis. It has more extensive involvement than most other variants. These other variants include linear porokeratosis, porokeratosis of Mibelli, punctate porokeratosis, porokeratosis palmaris et plantaris disseminata, and disseminated superficial porokeratosis. The eruptive form of porokeratosis is associated with malignancy, immunosuppression, and a proinflammatory state. Risk factors for porokeratosis include genetics, immunosuppression, and ultraviolet light. The lesions in disseminated superficial actinic porokeratosis start as pink to brown papules and macules with a raised border in sun-exposed areas that can be asymptomatic or slightly pruritic. There are many options for the treatment of disseminated superficial actinic porokeratosis, including topical diclofenac, photodynamic therapy (PDT), 5-fluorouracil (5-FU), imiquimod, vitamin D analogs, retinoids, and lasers. These lesions are considered precancerous. There is a 7.5 to 10% risk of malignant transformation to squamous cell carcinoma or basal cell carcinoma.
Disseminated superficial actinic porokeratosis (DSAP) is a disease of disordered keratinization. Disseminated superficial actinic porokeratosis is one of six variants of porokeratosis. It has more extensive involvement than most other variants. These other variants include linear porokeratosis, porokeratosis of Mibelli, punctate porokeratosis, porokeratosis palmaris et plantaris disseminata, and disseminated superficial porokeratosis. The eruptive form of porokeratosis is associated with malignancy, immunosuppression, and a proinflammatory state. Risk factors for porokeratosis include genetics, immunosuppression, and ultraviolet light. The lesions in disseminated superficial actinic porokeratosis start as pink to brown papules and macules with a raised border in sun-exposed areas that can be asymptomatic or slightly pruritic. There are many options for the treatment of disseminated superficial actinic porokeratosis, including topical diclofenac, photodynamic therapy (PDT), 5-fluorouracil (5-FU), imiquimod, vitamin D analogs, retinoids, and lasers. These lesions are considered precancerous. There is a 7.5 to 10% risk of malignant transformation to squamous cell carcinoma or basal cell carcinoma.
Indoda eneminyaka engama-52 ubudala, eyayisempilweni ngaphambili, yeza nebala elisicaba, elimise okwesangqa ekupheleni kwenzwane yakhe yesine, eyayikho iminyaka eyi-2 ngaphandle kokubangela iimpawu. Yaqala njengeqhuma elincinci, eliqinileyo kwaye lakhula ngaphandle ekuhambeni kwexesha. Ngaphandle kokuzama unyango olwahlukeneyo olunje nge-cryotherapy, iikhrimu, i-antifungal, kunye ne-antibiotics, isiqwenga asizange sibe ngcono. Ukuyihlolisisa ngokusondeleyo nge-dermocopsy kubonise indawo eyomileyo, ebomvu kunye nomda onzima, obunzima. Iqhekeza elincinci lesikhumba elithatyathwe kwincam yepetshi libonise ukukhula okungaqhelekanga kweseli kumaleko ongaphandle wolusu, eqinisekisa ukuxilongwa kwe porokeratosis of Mibelli.
A 52-year-old man with no past medical history presented with an asymptomatic annular atrophic patch on the distal portion of the fourth toe of 2 years’ duration. The lesion began as a small keratotic papule that gradually enlarged centrifugally. He had received multiple treatments including cryotherapy, topical corticosteroids, antifungals, and antibiotics without improvement. Dermoscopic examination revealed a scaly atrophic erythematous central area with a sharply demarcated peripheral hyperkeratotic structure. A skin biopsy of the edge of the lesion revealed a cornoid lamella with a column of parakeratotic cells extending from an invagination of the epidermis with absence of granular layer. The clinicopathologic correlation was consistent with porokeratosis of Mibelli.
A 52-year-old man with no past medical history presented with an asymptomatic annular atrophic patch on the distal portion of the fourth toe of 2 years’ duration. The lesion began as a small keratotic papule that gradually enlarged centrifugally. He had received multiple treatments including cryotherapy, topical corticosteroids, antifungals, and antibiotics without improvement. Dermoscopic examination revealed a scaly atrophic erythematous central area with a sharply demarcated peripheral hyperkeratotic structure. A skin biopsy of the edge of the lesion revealed a cornoid lamella with a column of parakeratotic cells extending from an invagination of the epidermis with absence of granular layer. The clinicopathologic correlation was consistent with porokeratosis of Mibelli.
Rhoqo kwenziwa i-biopsy kuba inokukhangeleka ifana ne-actinic keratosis okanye i-squamous cell carcinoma.